CELGZ Abraxis CVR
43,273,855 CVRs issued at $5.20 valuation. Cash payments up to $650m
$250m upon NSCLC approval with PFS claim ($5.77 per share)
$400m ($300m if after 4/1/2013) for approval in pancreatic cancer with OS claim ($9.24/$6.93 per share)
per calendar year ($2011 sales totaled $386m):
2.5% of sales between $1-2 B
5% of sales $2-3B
10% of sales >$3B
Final p3 NSCLC results at ASCO
http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1570826&highlight=
-US submission 12/9/11
-EU filling targeted 1h-2012
43,273,855 CVRs issued at $5.20 valuation. Cash payments up to $650m
$250m upon NSCLC approval with PFS claim ($5.77 per share)
$400m ($300m if after 4/1/2013) for approval in pancreatic cancer with OS claim ($9.24/$6.93 per share)
per calendar year ($2011 sales totaled $386m):
2.5% of sales between $1-2 B
5% of sales $2-3B
10% of sales >$3B
Final p3 NSCLC results at ASCO
http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1570826&highlight=
-US submission 12/9/11
-EU filling targeted 1h-2012
RSS Feed
